stockrow
Monday 9 November 2026
Export EVMN’s income statement to Excel — free account
Evommune Inc.
EVMNEvommune Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 85.7% from fiscal 2024.
- EPS
- +89.9%
- Free cash flow
- +21.8%
Quarter to June 2026, against a year earlier
6.65
0.28
+4.40%
Follow EVMN
Alert me
| Dec '24 | Dec '25 | |
|---|---|---|
P/E ratio |
0.00 | 0.00 |
Altman Z-Score |
— | 1.47 |
P/S ratio |
0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(6.99) | 9.47 |
P/FCF ratio |
0.00 | 0.00 |
P/Operating CF |
(3.24) | (6.29) |
P/B ratio |
0.00 | 0.51 |
Price to Tangible BV |
0.00 | 0.51 |
EV/Sales |
0.00 | 0.00 |
EV/EBITDA |
0.67 | 0.55 |
EV/Operating CF |
0.57 | 0.58 |
EV/FCF |
0.57 | 0.57 |
Quick Ratio |
2.57 | 8.33 |
Current Ratio |
2.64 | 8.57 |
Net Debt/EBITDA |
1.04 | 1.87 |
Debt/Assets |
0.70% | 0.08% |
Debt/Equity |
0.01 | 0.00 |
Asset Turnover |
0.00 | 0.09 |
Operating CF/Net income |
0.85 | 1.11 |
Capex/Depreciation |
(0.07) | (0.17) |
| 0.00% | (224.59%) | |
| 0.00% | (45.76%) | |
ROIC |
0.00% | (89.61%) |
Return on Tangible Assets |
(144.31%) | (50.43%) |
Average Days of Receivables |
0.00 | 0.00 |
Research and Development Expense of Revenue |
917.77% | 569.55% |
Selling, General and Administrative Expense of Revenue |
182.41% | 154.07% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
24.60% | 45.05% |
Graham Net Nets |
(5.94) | 1.28 |
Graham Number |
0.00 | 0.00 |
Earnings Yield |
(182.01%) | (162.30%) |
Free Cash Flow Yield |
(250.37%) | (73.06%) |
Revenue per Share |
4.64 | 2.12 |
Operating CF per Share |
(38.59) | (12.46) |
Capex per Share |
(0.06) | (0.04) |
Free Cash Flow per Share |
(38.65) | (12.49) |
Cash per Share |
47.77 | 24.31 |
Shareholders Equity per Share |
31.52 | 33.50 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
31.52 | 33.50 |
Free Cash Flow |
(58.28) | (76.68) |
Working Capital |
46.01 | 135.57 |
Capital Expenditures |
(0.09) | (0.23) |
Net Current Asset Value |
45.47 | 134.10 |
EV/EBIT |
0.66 | 0.54 |
Capex to Sales |
0.01 | 0.02 |
Price to Operating Income |
0.00 | 0.00 |
| Other line items | ||
Depreciation/Fixed assets |
0.97 | 1.40 |
Cash ROIC |
(48.52%) | (21.60%) |
Accounts Receivable Turnover |
0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Average Payables |
— | 8.01 |
Average Assets |
— | 150.50 |
Average Common Equity |
— | 30.66 |
Columns are period end dates · fundamentals updated 25 Oct 2026